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Introduction
Nowadays, neuromodulation offers different devices 
and techniques in the treatment of neurological patients 
suffering from paroxysmal disorders, such as epilepsy and 
migraine. rTMS has shown good results among other non-
pharmacologic therapies.  Transcranial magnetic stimula-
tion (TMS) was introduced for the first time in 1985, as a 
method of noninvasive stimulation of the human cortex [1, 
2], offering the possibility of studying the connection be-
tween the anatomical and functional elements of the human 
cortex [3].  Currently, rTMS is considered a useful tool in 
the management and treatment of several disorders origi-
nating in the cerebral cortex [4]. The small intensity cur-
rents induced by the magnetic field have an impact on vari-
ous mechanisms at cellular level being able to change the 
expression of neurotransmitters, thus resulting in modula-
tion of pathophysiological pathway of migraine. 
The primary mechanisms causing migraine attacks 
still remain largely unrecognized due to the complex and 
dynamic organization of processes in the brain neuronal 
networks. Cortical excitability has been suggested to be 
dysfunctional in patients with migraine [5]. The ability to 
modulate cortical activity and induce persistent, plastic ef-
fects renders repetitive transcranial magnetic stimulation 
(rTMS) as a potential therapeutic approach.
DOI: 10.5281/zenodo.4018912
UDC: 616.857
neuromodulatory approach in paroxysmal neurological disorders
1,2Pavel Leahu, 1Stanislav groppa
1Department of Neurology No 2, Nicolae Testemitanu State University of Medicine and Pharmacy
Chisinau, the Republic of Moldova
2 Emergency Medicine Institute, Chisinau, the Republic of Moldova
Authors’ ORCID iDs, academic degrees and contributions are available at the end of the article
*Corresponding author: leahu.pavel@gmail.com
Manuscript received August 10, 2020; revised manuscript September 14, 2020; published online October 02, 2020
Abstract
Background: Nowadays, neuro-modulation offers different devices and techniques in the treatment of neurological patients suffering from paroxysmal 
disorders, such as epilepsy and migraine. Among non-pharmacologic therapies, rTMS shows good results. 
Material and methods: A longitudinal, double-blinded, rTMS-intervention study was conducted on 42 subjects with episodic migraine (with and without 
aura, 2-14 attacks per month). After a baseline follow-up for 1 month, subjects had 6 sessions of rTMS during 2 weeks and received multifocal rTMS or 
sham stimulation, with further  3-month assessment via questionnaires on headache frequency .
Results: After stimulation, the real rTMS group showed a reduction in the number of attacks – 7.5 ± 3.7 at baseline to 3.8 ± 2.7 attacks at 3 months’ period 
(p<0.05) with an effect lasting at least three months. The number of attacks was also reduced in the placebo group (7.3 ± 3.6 to 4.4 ± 2.9) (p>0.05). There 
was a significant reduction in the intensity of attacks over 4-week therapy in the treatment group (6.7 ± 1.5 at baseline; 5.3 ± 2.5 at 4 weeks (p<0.05). The 
conducted questionnaires revealed a positive impact on quality of life and functional outcomes. There were no serious adverse events reported. 
Conclusions: Our study showed evidence that the experimental rTMS protocol significantly reduced the frequency and intensity of migraine attacks 
compared to placebo treatment with no serious adverse events.
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Several studies demonstrate that TMS can reduce the 
frequency and severity of migraine attacks [6, 7]. Possible 
mechanisms involve induction effects on blood-flow, pe-
ripheral nerve sensing, cortical excitability and the release 
of cytokines or inflammatory neuropeptides [8-10].
The purpose of our study was to evaluate the efficacy and 
tolerability of multifocal rTMS for migraine prevention. The 
study hypothesis states that multifocal rTMS reduces the 
frequency and intensity of migraine attacks in comparison 
to a baseline period, and that this effect exceeds a possible 
placebo effect. Furthermore, it hypothesized that this stimu-
lation protocol can induce improvements in quality of life 
scores: Headache impact test 6 (HIT-6), Migraine disability 
index score (MDIS), and Headache disability index (HDI).
Material and methods
A longitudinal, double-blinded, rTMS-intervention 
study was conducted on subjects with episodic migraine 
(both with and without aura, 2-14 attacks per month). 
The research project was approved by the Research Ethics 
Committee of Nicolae Testemitanu State University of 
Medicine and Pharmacy (No 90 of June 19, 2018). After a 
4-week baseline period, the subjects underwent 6 interven-
tion sessions within 2 weeks to receive either multifocal ex-
perimental rTMS or a placebo-treatment (randomized trial 
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was performed by a researcher blinded to every aspect of 
the study except randomization codes). The blinding of sub-
jects was performed by means of a specific round biconcave 
active/placebo coil, which depending on the randomization 
code could act as an active coil (applying the experimental 
protocol) or sham (that was vibrating and making sounds 
imitating the real rTMS stimulation). A total number of 
forty-two subjects were eligible to participate in the study. 
The overall group baseline description is presented in table 
1 and age-related group distribution in figure 1.
The test findings were evaluated via the IBM SPSS 
Statistics v. 23, Microsoft Office Excel program; the Student-
test was applied to process the statistical mean values, re-
peated measures ANOVAs were performed separately for 
both groups. To determine the statistical significance, the P 










Female, n (%)   19 (86.3%) 20 (100%)
Age in years (M ± SD)   38.4 ± 10.2 41 ± 12.6
Range   20 – 58 22 - 62
Headache frequency per 
month (M ± SD)
  7.5 ± 3.7  7.3 ± 3.6
Range    2 – 14 3 – 14 
Pain intensity (M ± SD)    6.7 ± 1.5  6.2 ± 1.2
*HIT-6 (M ± SD)    63.4 ± 6.3  64.2 ± 4.4
• HDI (M ± SD)    64.2 ± 17.4  55.4 ± 22
†MIDAS (M ± SD)    36.5 ± 22.9 35.9 ± 23.9 
* – Headache Impact Test, • – Headache Disability Index, † – Migraine 
Disability Assessment Score.
 Fig. 1.  Age group distribution. Subjects aged 36-45 years old 
were registered as the dominant age group, data similar  
to those presented in other studies
Study design
After signing the informed consent, subjects were asked 
to fill out a headache diary for 4 weeks and complete the 
HDI, HIT-6, and MDIS questionnaire prior to the first stim-
ulation session. Frequency and severity of migraine attacks 
assessed within the 8 weeks, following the intervention serve 
as primary outcome variables. Quality of life questionnaires 



























Frequency                 Frequency                Frequency             Frequency             Freuency                 
VAS                           VAS                         VAS                     VAS                       VAS 
PGIC                          PGIC                        PGIC                    PGIC                      PGIC 
                                   HIT-6                       HIT-6                   HIT-6                     HIT-6 
                                   Diary                        HDI                      MIDAS                  HDI 
                                                                    Diary                    Diary                     MIDAS 
                                                                                               Diary                        
            Week -4                       2 weeks      0       2 weeks              4 weeks                   8 weeks          12 weeks              24 weeks      
Follow-up: primary and secondary variables rTMS 
Primary outcome End of study 
Alternate days 
Fig. 2.  Study design
Stimulation protocol
The stimulation protocol consisted of 2 steps, a swipe-
stimulation and a spot burst stimulation. High frequency 
rTMS comprised 140 pulses/train in trains at 60% of mo-
tor threshold, followed by 5 pulses/train in trains at 85% of 
motor threshold, applied over cortex within a predefined 
multifocal delivery scheme consisting of 11 points marked 
on individual caps according to the 10-20 EEG system dur-
ing the first session (fig. 3).
Fig. 3.  graphic representation of the experimental stimulation 
protocol (neurophysiology Laboratory, Department of 
neurology, Emergency Medicine Institute)
Safety
Stimulation procedures had been performed respecting 
the IFCN committee safety protocols and recommendations 
[12].
Results
42 eligible subjects were included in the data analysis. 
After stimulation, the real rTMS group showed a reduction 
in the number of attacks – 7.5 ± 3.7 at baseline to 3.8 ± 2.7 
attacks at 3 months’ period (p<0.05). The effect lasted at 
least three months. 
The number of attacks was also reduced in the placebo 
group (7.3 ± 3.6 to 4.4 ± 2.9) (p>0.05). There was a signifi-
cant reduction in the intensity of attacks at 4 weeks after the 
treatment in the treatment group (6.7 ± 1.5 at baseline; 5.3 
± 2.5 at 4 weeks (p<0.05). The primary outcome results are 
presented in fig. 5. The assessment of secondary outcomes 
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in real rTMS group had shown an overall reduction in all 
variables: HIT-6 scores – 63.4 ± 6.3 at baseline to 54.1 ± 
8.3 at 12 weeks, compared to sham group – 64.2 ± 4.4 at 
baseline to 56.7 ± 8.9 at 12 weeks follow-up; HDI real rTMS 
64.2 ± 17.4 at baseline to 48.5 ± 24.5 at 8 weeks vs 55.4 ± 
22.1 at baseline to 40.7 ± 24.1 at 8 weeks; the same effect 
was observed in MIDAS scores – real rTMS group 36.5 ± 
22.9 at baseline to 20.9 ±  23.2 at 12 weeks vs 35.9 ± 25.9 at 
baseline to 19.4 ±  19.2 at 12 weeks in sham rTMS group. 
The conducted questionnaires revealed a positive impact on 
quality of life and functional outcome in both groups, more 
prominent in the real rTMS group but with no statistical 
inter-group difference (p>0.05). There were no serious ad-
verse events reported.
Discussion
This present study hypothesized that the observed posi-
tive effect in the reduction of headache frequency and in-
tensity of the real (experimental) rTMS protocol compared 
to placebo could be explained by the changes in the cortical 
excitability and function obtained by direct cortical mag-
netic stimulation [8] as well as by the modulatory effect on 
peripheral nerve sensing activity (ophthalmic branch of the 
trigeminal nerve and greater occipital nerve (C2)) [9]. The 
changes in the assessment questionnaires of quality of life 
(HIT-6, HDI, MIDAS) could be partially explained by the 
improvement in primary outcomes (headache frequency 
and intensity) [13] as well as by the modulation of cortical 
areas engaged in mood and affective behavior [14-17]. One 
of the limitations of the study is the relatively small number 
of analyzed subjects, as well as the fact that assessment by 
such scales as HIT-6, HDI and MIDAS, though a standard 
in migraine research, carries a subjective recall bias in both 
groups [18]. In addition, based on the novelty of the rTMS 
as a treatment option, another possible bias could be con-
sidered high subject treatment expectations [19]. Further 
research is needed in order to confirm the experimental 
rTMS protocol usefulness and non-inferiority to already ex-
isting therapeutic TMS protocols [20].
Conclusions
Our study showed compelling evidence that the experi-
mental rTMS paradigm reduces the number and severity of 
migraine attacks compared to placebo treatment. Multifocal 
rTMS should be considered a novel and effective preven-
tion treatment approach for paroxysmal disorders, such as 
episodic migraine in adults. An important fact is that the 
experimental protocol was well tolerated and showed no se-
rious adverse events.
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